Abstract
Amikacin is a frequently used antibiotic in the treatment of peritoneal dialysis (PD)-related peritonitis. Ototoxicity is a well-known complication of amikacin for which increased oxidative stress and free oxygen radicals are thought to be responsible. In this study, the effect of N-acetyl-cysteine (NAC) on cochlear function and oxidant situation in the amikacin related ototoxicity in PD-related peritonitis patients are investigated. Forty-six patients who had their first PD-related peritonitis attacks receiving empirical amikacin treatment were enrolled in the study. The patients were randomized into two groups; the first group (n = 23) as NAC receiving and the second group (n = 23) as a placebo receiving, control group. Otoacoustic emissions were measured before, 1 week after and 4 weeks after the treatment. Oxidative stress measurements were performed concurrently in order to evaluate the effectiveness of NAC. The results of screening with otoacoustic emission testing after amikacin treatment showed that cochlear function is protected especially in higher frequencies in NAC group when compared with the control group. Evaluation of the antioxidant status of the two groups showed no differences in the basal values, but at the first week there was an increase in the NAC group compared with the control group, and this increase became significant at the fourth week. NAC is found to be safe and effective in amikacin-related ototoxicity in patients with PD-related peritonitis. We suggest a close monitoring of the patients receiving amikacin containing treatment protocols and if amikacin is administrated supplementing the treatment with NAC.
Similar content being viewed by others
References
Fried LF, Bernardini J, Johnston JR et al (1996) Peritonitis influences mortality in peritoneal dialysis patients. J Am Soc Nephrol 67:2176–2182
Woodrow G, Turney JH, Brownjohn AM (1997) Technique failure in peritoneal dialysis and its impact on patient survival. Perit Dial Int 17:360–364
Bayston R, Andrews M, Rigg K (1999) Recurrent infection and catheter loss in patients on continuous ambulatory peritoneal dialysis. Perit Dial Int 19:550–555
Li PKT, Szeto CC, Piraino B et al (2010) Peritoneal dialysis-related infections recommendations, update 2010. Perit Dial Int 30:393–423
Guthrie OW (2008) Aminoglycoside induced ototoxicity. Toxicology 249:91–96
Rizzi MD, Hirose K (2007) Aminoglycoside ototoxicity. Curr Opin Otolaryngol Head Neck Surg 15:352
Gailiunas P Jr, Dominguez-Moreno M, Lazarus JM et al (1978) Vestibular toxicity of gentamicin: incidence in patients receiving long-term hemodialysis therapy. Arch Intern Med 138:1621
Tokgoz B, Somdas MA, Ucar C et al (2010) Correlation between hearing loss and peritonitis frequency and administration of ototoxic intraperitoneal antibiotics in patients with CAPD. Ren Fail 32:179–184
Sinswat P, Wu WJ, Sha SH et al (2000) Protection from ototoxicity of intraperitoneal gentamicin in guinea pig. Kidney Int 58:2525–2532
Garetz SL, Altschuler RA, Schacht J et al (1994) Attenuation of gentamicin ototoxicity by glutathione in the guinea pig in vivo. Hear Res 77:81–87
Fetoni AR, Sergi B, Scarano E et al (2003) Protective effects of α-tocopherol against gentamicin-induced oto-vestibulo toxicity: an experimental study. Acta Otolaryngol 123:192–198
Weinbroum AA, Rudick V, Ben-Abraham R et al (2000) N-acetyl-l-cysteine for preventing lung reperfusion injury after liver ischemia–reperfusion: a possible dual protective mechanism in a dose-response study. Transplantation 69:853
Prescott L, Illingworth R, Critchley J et al (1979) Intravenous N-acetylcystine: the treatment of choice for paracetamol poisoning. Br Med J 2:1097–1100
Feldman L, Efrati S, Eviatar E et al (2007) Gentamicin-induced ototoxicity in hemodialysis patients is ameliorated by N-acetylcysteine. Kidney Int 72:359–363
Tokgoz B, Ucar C, Kocyigit I et al (2011) Protective effect of N-acetylcysteine from drug-induced ototoxicity in uraemic patients with CAPD peritonitis. Nephrol Dial Transpl 26:4073–4078
Kosecik M, Erel O, Sevinc E et al (2005) Increased oxidative stress in children exposed to passive smoking. Int J Cardiol 100:61–64
Black F, Pesznecker S (1993) Vestibular ototoxicity. clinical considerations. Otolaryngol Clin N Am 26:713–736
Fausti SA, Henry JA, Schaffer HI et al (1992) High-frequency audiometric monitoring for early detection of aminoglycoside ototoxicity. J Infect Dis 165:1026
Schacht J (1993) Biochemical basis of aminoglycoside ototoxicity. Otolaryngol Clin N Am 26:845–856
Hashino E, Shero M, Salvi RJ (1997) Lysosomal targeting and accumulation of aminoglycoside antibiotics in sensory hair cells. Brain Res 777:75–85
Hirose K, Hockenbery DM, Rubel EW (1997) Reactive oxygen species in chick hair cells after gentamicin exposure in vitro. Hear Res 104:1–14
Schacht J (1999) Antioxidant therapy attenuates aminoglycoside-induced hearing loss. Ann NY Acad Sci 884:125
Schacht J (1998) Aminoglycoside ototoxicity: prevention in sight? Otolaryngol Head Neck Surg 118:674
Sha SH, Taylor R, Forge A et al (2001) Differential vulnerability of basal and apical hair cells is based on intrinsic susceptibility to free radicals. Hear Res 155:1–8
Erel O (2004) A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clin Biochem 37:277–285
Buyukhatipoglu H, Sezen Y, Yildiz A et al (2010) N-acetylcysteine fails to prevent renal dysfunction and oxidative stress after noniodine contrast media administration during percutaneous coronary interventions. Pol Arch Med Wewn 120:383–389
Black FO, Pesznecker S, Stallings V (2004) Permanent gentamicin vestibulotoxicity. Otol Neurotol 25:559
Campbell KCM (2004) Audiologic monitoring for ototoxicity. In: Roland PS, Rutka JA (eds) Ototoxicity. BC Decker, pp 154–160
Probst R, Lonsbury-Martin BL, Martin GK (1991) A review of otoacoustic emissions. J Acoust Soc Am 89:2027–2067
Kemp DT, Ryan S, Bray P (1990) A guide to the effective use of otoacoustic emissions. Ear Hear 11:93
Feldman L, Sherman RA, Weissgarten J (2012) N-Acetylcysteine use for amelioration of aminoglycosides-induced ototoxicity in dialysis patients. Semin Dial 25:491–494
Tepel M, Van Der Giet M, Schwarzfeld C et al (2000) Prevention of radiographic contrast agent induced reductions in renal function by acetylcysteine. N Engl J Med 343:180–184
Feghali JG, Liu W, Van De Water TR (2001) l-N-acetyl-cysteine protection against cisplatin-induced auditory neuronal and hair cell toxicity. Laryngoscope 111:1147–1155
Thomas Dickey D, Muldoon LL, Kraemer DF et al (2004) Protection against cisplatin-induced ototoxicity by N-acetylcysteine in a rat model. Hear Res 193:25–30
Maniu A, Perde-Schrepler M, Cosgarea M (2011) Protective effect of l-N-acetylcysteine against gentamycin ototoxicity in the organ cultures of the rat cochlea. Rom J Morphol Embryol (Revue roumaine de morphologie et embryologie) 52:159–164
Bock GR, Yates GK, Miller JJ et al (1983) Effects of N-acetylcysteine on kanamycin ototoxicity in the guinea pig. Hear Res 9:255–262
Acknowledgments
This study is registered with the name of ‘Protective Effect of N-acetylcysteine Against Ototoxicity’ on clinicaltrials.gov with identifier the number of NCT01271088. We thank to Dr. Ferhan Elmali for his kind help and contribution to the statistical analysis of the data. We also thank to the PD nurses of the PD department for their dedicated efforts.
Conflict of interest
The authors declare that they have no competing interests.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kocyigit, I., Vural, A., Unal, A. et al. Preventing amikacin related ototoxicity with N-acetylcysteine in patients undergoing peritoneal dialysis. Eur Arch Otorhinolaryngol 272, 2611–2620 (2015). https://doi.org/10.1007/s00405-014-3207-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00405-014-3207-z